OmanDocSign in

Curriculum · Metabolic and Endocrine and Diabetes Mellitus

Onset, peak and duration of insulin preparations

What it is

The common insulin preparations are told apart by their pharmacokinetic profiles, that is by peak onset and effective duration, and they fall into rapid, short, intermediate and long acting groups.

How it is treated

The best regimen of insulin is the basal bolus one. In women with diabetes undergoing induction of labour or cesarean section, short acting insulin is used and NPH is avoided.

Reading these profiles against the clock is what they are for. A low that comes on about eight hours after the dose falls inside the 6 to 10 hour peak onset of NPH, and outside the 0.5 to 1.5 hours of lispro and the 2 to 3 hours of regular insulin, while glargine has no peak effect at all. The hour of the low, counted from the hour of the dose, names the preparation.

Which one is the prandial insulin is decided by the principle and by the timing rule that follows it. Insulin therapy rests on a basal insulin, which suppresses glucose production from gluconeogenesis, and a bolus, prandial or meal-time insulin, which limits hyperglycemia after a meal. Short acting insulin, regular, is injected 30-45 minutes before the meal; the rapid acting insulin analogues, lispro, aspart and glulisine, are injected 10-20 minutes before the meal; and basal insulin can be injected without relation to any meal. So glulisine is a meal-time insulin and glargine is not.

Two tables in the national guideline give these preparations their own numbers, and where they differ from the slide it is these that are worked to. The first classifies them as bolus and basal. Bolus: the rapid ones, lispro, aspart and glulisine, onset 15 mins, peak 1 to 1.5 hrs, duration 3 to 4 hrs; and the short one, regular, onset 30-60 mins, peak 2 to 3 hrs, duration 6 to 8 hrs. Basal: the intermediate one, isophane or NPH, onset 2 to 4 hrs, peak 5 to 8 hrs, duration up to 12 hrs; and the long-acting ones, glargine, onset 2 to 4 hrs and duration 22-24 hrs, glargine U300, onset up to 6 hrs and duration up to 36 hrs, detemir, onset 1 to 2 hrs and duration up to 24 hrs, and degludec, onset 2 to 3 hrs and duration up to 36-42 hrs. In that first table the peak is empty for all four long-acting preparations. The pre-mix preparations carry their own numbers in the same table: mixtard 30/70, onset 30-60 mins, peak 4 to 8 hrs, duration up to 12 hrs; lispro pre mix 50/50, onset 15 mins, peak 1 to 1.5 hrs, duration up to 22 hrs; aspart mix 30/70, onset 15 mins, peak 1.5 to 2 hrs, duration up to 12 hrs; and degludec/aspart 30/70, onset 15 mins, peak 3 to 5 hrs, duration up to 36-42 hrs.

The second table fills the peak in, and it is there that they are separated. Glargine peaks at 8 to 12 h and detemir at 4 to 7 h, while glargine U300 and degludec are both written as minimal peak, degludec with an onset of 0.5 to 1.5 h and a duration above 42 h. So among the basal preparations it is degludec, with glargine U300, that has effectively no peak, and glargine and detemir do peak. The same table gives NPH a peak of 4 to 12 h with a duration of 12 to 24 h, regular a peak of 2 to 4 h with a duration of 5 to 8 h, the rapid-acting analogs a peak of 1 to 3 h, and adds an ultra rapid acting analog, faster aspart, with an onset of 0.1 to 0.2 h.

Two of these matter when the hour of a low is read back to a preparation. The slide gives glargine no peak, in the first table its peak is empty, and the second table gives it a peak of 8 to 12 h; the words minimal peak belong in that second table to glargine U300 and degludec. And the slide gives NPH a peak onset of 6 to 10 hours where the tables give 5 to 8 hrs and 4 to 12 h, so a low at about eight hours after the dose still sits inside NPH on all three.